Nutriband's aversa(tm) buprenoprhine may reach peak annual sales of $70-130 million based on market assessment by leading healthcare consulting firm

Orlando, fl / accesswire / october 11, 2023 / nutriband inc. (nasdaq:ntrb)(nasdaq:ntrbw), a company engaged in the development of transdermal pharmaceutical products, today announced it has completed the market assessment and commercialization strategy for aversa™ buprenorphine, an abuse deterrent buprenorphine transdermal system. the company engaged leading healthcare consulting company health advances to assess the market opportunity and commercial strategy for aversa™ buprenorphine, which has the potential to be the world's first buprenorphine transdermal system with abuse deterrent properties.
NTRB Ratings Summary
NTRB Quant Ranking